MF-438 (MF438) is a potent and orally bioavailable stearoyl-CoA desaturase 1 (SCD1) inhibitor with IC50 of 2.3 nM.
Co-treatment with cisplatin and the SCD1 inhibitor MF-438 reverts upregulation of lung cancer CSCs markers, strongly synergizes in the inhibition of 3D spheroids formation and induces CSCs apoptosis.
MF-438 exhibits good pharmacokinetics and metabolic stability.
MF-438 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma.
